Edition:
India

Dr.Reddy's Laboratories Ltd (REDY.BO)

REDY.BO on Bombay Stock Exchange

2,363.35INR
17 Aug 2018
Change (% chg)

Rs15.40 (+0.66%)
Prev Close
Rs2,347.95
Open
Rs2,365.15
Day's High
Rs2,410.00
Day's Low
Rs2,352.00
Volume
101,567
Avg. Vol
105,451
52-wk High
Rs2,611.80
52-wk Low
Rs1,888.00

Latest Key Developments (Source: Significant Developments)

India's Dr.Reddy's Laboratories June-Qtr Consol Net Profit After Tax Rises Over 7-fold
Thursday, 26 Jul 2018 

July 26 (Reuters) - Dr.Reddy's Laboratories Ltd ::JUNE QUARTER CONSOL NET PROFIT AFTER TAX 4.76 BILLION RUPEES VERSUS PROFIT OF 666 MILLION RUPEES LAST YEAR.CONSENSUS FORECAST FOR JUNE QUARTER CONSOL NET PROFIT WAS 2.98 BILLION RUPEES.JUNE QUARTER CONSOL NET SALES 36.51 BILLION RUPEES VERSUS 32.49 BILLION RUPEES LAST YEAR.  Full Article

Dr.Reddy's Laboratories Launches Esomeprazole Magnesium Delayed-Release Capsules USP, 20 Mg In U.S. Market
Friday, 20 Jul 2018 

July 20 (Reuters) - Dr.Reddy's Laboratories Ltd ::DR.REDDY'S LABORATORIES LTD ANNOUNCES LAUNCH OF ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES USP, 20 MG IN THE U.S. MARKET.  Full Article

Dr.Reddy's Says No Direct Financial Implication To Compensation And/Or Penalty On Patent Infringement Case With Indivior
Tuesday, 17 Jul 2018 

July 17 (Reuters) - Dr.Reddy's Laboratories Ltd ::CLARIFIES REGARDING NEWS ITEM ON PATENT INFRINGEMENT CASE WITH INDIVIOR.SAYS THERE IS NO DIRECT FINANCIAL IMPLICATION RELATING TO COMPENSATION AND/OR PENALTY.IF CO WINS ULTIMATELY, CO WILL BE REIMBURSED FOR POTENTIAL LOSSES INCURRED FOR NOT BEING ABLE TO SELL GENERIC PRODUCTS.WILL NOT REALIZE FINANCIAL BENEFITS OWING TO STOP IN SALES OF GENERIC VERSIONS OF SUBOXONE SUBLINGUAL FILM.IF CO LOSES THE CASE, THE PLATIFF MAY CLAIM LOSES ON ACCOUNT OF CO'S SALES RECORDED DURING BRIEF PERIOD BETWEEN LAUNCH DATE AND TRO DATE.  Full Article

Indivior Granted Preliminary Injunction On Generic (Buprenorphine And Naloxone) Sublingual Film
Saturday, 14 Jul 2018 

July 13 (Reuters) - Indivior PLC ::INDIVIOR IS GRANTED PRELIMINARY INJUNCTION ON GENERIC (BUPRENORPHINE AND NALOXONE) SUBLINGUAL FILM.INDIVIOR IS GRANTED PRELIMINARY INJUNCTION ON GENERIC (BUPRENORPHINE AND NALOXONE) SUBLINGUAL FILM.U.S. DISTRICT COURT FOR DISTRICT OF NEW JERSEY HAS GRANTED A PRELIMINARY INJUNCTION (PI) AGAINST DR. REDDY'S LABORATORIES.RESTRICTIONS OF PREVIOUSLY ENTERED TEMPORARY RESTRAINING ORDER (TRO) REMAIN IN PLACE.COURT ALSO ORDERED INDIVIOR TO POST BOND TO PROVIDE SECURITY TO DRL SHOULD COURT CONCLUDE THAT '305 PATENT IS INVALID AND/OR NOT INFRINGED.DR.REDDY'S IS UNABLE TO SELL ITS GENERIC BUPRENORPHINE/NALOXONE SUBLINGUAL FILM PRODUCT, PENDING OUTCOME OF LITIGATION AGAINST DRL.COURT HAS ALSO ORDERED PARTIES TO SUBMIT A FINAL PROPOSED INJUNCTION ORDER ON MONDAY, JULY 16.  Full Article

Dr.Reddy's Laboratories Enters Agreement With UCB India To Co-Promote, Distribute Epilepsy Drug In India
Monday, 9 Jul 2018 

July 9 (Reuters) - Dr.Reddy's Laboratories Ltd ::CO, UCB INDIA ENTER AGREEMENT TO CO-PROMOTE AND DISTRIBUTE BRIVIACT, DRUG FOR TREATMENT OF EPILEPSY IN INDIA.  Full Article

India's Dr.Reddy's Laboratories Launches Repatha In India
Monday, 2 Jul 2018 

July 2 (Reuters) - Dr.Reddy's Laboratories Ltd ::ANNOUNCES LAUNCH OF REPATHA IN INDIA.IN INDIA, REPATHA IS DISTRIBUTED BY DR. REDDY'S AND MANUFACTURED BY AMGEN.REPATHA IS INDICATED FOR TREATMENT OF ADULT PATIENTS WITH PRIMARY HYPERCHOLESTEROLAEMIA OR MIXED DYSLIPIDAEMIA.  Full Article

Dr.Reddy's Labs Extends Temporary Restraining Order W.R.T. Generic Buprenorphine, Naloxone Sublingual Film
Friday, 29 Jun 2018 

June 29 (Reuters) - Dr.Reddy's Laboratories Ltd ::EXTENDED TEMPORARY RESTRAINING ORDER FOR 14 DAYS W.R.T. GENERIC BUPRENORPHINE, NALOXONE SUBLINGUAL FILM IN U.S. MARKET.  Full Article

Indivior - U.S. District Court Heard Co's Application For A Preliminary Injunction Against Dr. Reddy's Lab
Friday, 29 Jun 2018 

June 28 (Reuters) - Indivior PLC ::INDIVIOR PLC - U.S. DISTRICT COURT FOR DISTRICT OF NEW JERSEY HEARD CO'S APPLICATION FOR A PRELIMINARY INJUNCTION AGAINST DR. REDDY'S LABORATORIES.  Full Article

Dr.Reddy's Laboratories Gets EIR From U.S. FDA For 2 Facilities
Thursday, 28 Jun 2018 

June 28 (Reuters) - Dr.Reddy's Laboratories Ltd ::SAYS CO GOT EIR FROM U.S. FDA FOR API HYDERABAD PLANT 3, API HYDERABAD PLANT 1.  Full Article

U.S. District Court Rules In Favor Of Lilly In Alimta Vitamin Regimen Patent Lawsuit
Saturday, 23 Jun 2018 

June 22 (Reuters) - Eli Lilly and Co ::U.S. DISTRICT COURT RULES IN FAVOR OF LILLY IN ALIMTA VITAMIN REGIMEN PATENT LAWSUIT.ELI LILLY - RULINGS MEAN DR. REDDY'S LABORATORIES & HOSPIRA WILL BE PREVENTED FROM LAUNCHING ALTERNATIVE SALT FORMS OF PEMETREXED UNTIL PATENT EXPIRES.ELI LILLY AND CO - U.S. COURT'S RULING ON ALIMTA VITAMIN REGIMEN PATENT LAWSUIT CAME IN CASE OF ELI LILLY AND COMPANY V. DR. REDDY'S LABORATORIES.ELI LILLY AND CO - EXPECTS DR. REDDY'S LABORATORIES AND HOSPIRA TO APPEAL RULING.ELI LILLY AND CO - ON JUNE 15, U.S. DISTRICT COURT ALSO RULED IN FAVOR OF LILLY IN CASE OF ELI LILLY AND COMPANY VERSUS HOSPIRA.ELI LILLY AND CO - RULING DENIED HOSPIRA'S MOTION FOR SUMMARY JUDGEMENT AND GRANTING LILLY'S CROSS-MOTION FOR SUMMARY JUDGEMENT.  Full Article

Indivior: U.S. court rules against generic rival's appeal

Indivior Plc notched a legal victory on Tuesday after a U.S. court reaffirmed that a generic rival could not re-launch cheaper versions of the British drugmaker's best-selling opioid addiction treatment in the United States.